Charles-Antoine Guelluy

Mr. Guelluy's experience includes advising:

• Imerys, the world leader in mineral-based specialty solutions for industry, in its exclusive negotiations to sell its High Temperature Solutions business (HTS) to Platinum Equity
• Fortress Investment Group in the restructuring of Football Club des Girondins de Bordeaux (Bordeaux FC)
• Farallon Capital as subscriber of GreenYellow’s issue of €109 million convertible bonds with warrants attached; GreenYellow is a leading energy transition company and subsidiary of Casino Group
• Certares in the context of the backing process of the Pierre & Vacances – Center Parcs group 
• Bloom & Wild in its acquisition of Bergamotte, Europe’s leading online flower company
• Fortress Investment Group on the sale and refinancing of Bordeaux FC, a French professional football team
• Veracyte in its acquisition of HalioDx, a French immuno-oncology diagnostics company
• Public Sector Pension Investment Board in its acquisition with La Caisse de Dépôt et Placement du Québec of undisclosed minority stake in Fives, a France-based industrial engineering company
• Groupe Bertrand in connection with Burger King France and quick refinancing of existing indebtedness
• Air Liquide in its investment in CellNovo, a France and UK-based company that has developed the first connected all in one diabetes management system
• Andromède in the context of an equity investment in Alboran
• Andromède in its acquisition of Verquin Reims Cathédrale, a France-based hotel located in Reims
• Intermediate Capital Group and Sagesse Retraite Santé in their acquisition of a majority stake in DomusVi, a France-based provider of services to elderly people including nursing homes, residential facilities, and home care
• MédiPôle Partenaires SAS, a France-based owner and operator of private hospitals and health care facilities, in the minority investment of BPI France into the group
• Sodalis S.r.l. in its acquisition of Inventia, a France-based manufacturer and distributor of hygiene and beauty products
• Ardian in relation with the acquisition of the biologist group, Bio 7, from Chequers Capital